Shandong Xinhua Pharmaceutical Stock Net Income
| 000756 Stock | 15.70 0.82 4.96% |
Shandong Xinhua Pharmaceutical fundamentals help investors to digest information that contributes to Shandong Xinhua's financial success or failures. It also enables traders to predict the movement of Shandong Stock. The fundamental analysis module provides a way to measure Shandong Xinhua's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shandong Xinhua stock.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 506.1 M | 328.4 M | |
| Net Income Applicable To Common Shares | 400.8 M | 258.3 M | |
| Net Income | 496.5 M | 311.8 M |
Shandong | Net Income |
Shandong Xinhua Pharmaceutical Company Net Income Analysis
Shandong Xinhua's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Shandong Xinhua Net Income | 496.51 M |
Most of Shandong Xinhua's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shandong Xinhua Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Shandong Operating Income
Operating Income |
|
Based on the recorded statements, Shandong Xinhua Pharmaceutical reported net income of 496.51 M. This is 45.48% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all China stocks is 13.04% higher than that of the company.
Shandong Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shandong Xinhua's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shandong Xinhua could also be used in its relative valuation, which is a method of valuing Shandong Xinhua by comparing valuation metrics of similar companies.Shandong Xinhua is currently under evaluation in net income category among its peers.
Shandong Fundamentals
| Return On Equity | 0.0942 | ||||
| Return On Asset | 0.0356 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 9.18 B | ||||
| Shares Outstanding | 487.41 M | ||||
| Shares Owned By Insiders | 50.60 % | ||||
| Shares Owned By Institutions | 0.97 % | ||||
| Price To Book | 2.20 X | ||||
| Price To Sales | 1.05 X | ||||
| Revenue | 8.1 B | ||||
| Gross Profit | 2.04 B | ||||
| EBITDA | 1.01 B | ||||
| Net Income | 496.51 M | ||||
| Total Debt | 283.96 M | ||||
| Book Value Per Share | 7.14 X | ||||
| Cash Flow From Operations | 265.28 M | ||||
| Earnings Per Share | 0.65 X | ||||
| Target Price | 13.95 | ||||
| Number Of Employees | 7.1 K | ||||
| Beta | -0.022 | ||||
| Market Capitalization | 8.72 B | ||||
| Total Asset | 8.29 B | ||||
| Retained Earnings | 2.31 B | ||||
| Working Capital | 828.33 M | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 8.29 B | ||||
| Last Dividend Paid | 0.28 |
About Shandong Xinhua Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shandong Xinhua Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shandong Xinhua using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shandong Xinhua Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Shandong Stock
Shandong Xinhua financial ratios help investors to determine whether Shandong Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shandong with respect to the benefits of owning Shandong Xinhua security.